OOIR: Observatory of International Research

Papers

(The H4-Index of npj Precision Oncology is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Machine learning approaches to drug response prediction: challenges and recent progress	158
3D bioprinting for reconstituting the cancer microenvironment	153
Classification and mutation prediction based on histopathology H&E images in liver cancer using deep learning	113
Patient-derived organoids as a predictive biomarker for treatment response in cancer patients	107
Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer	76
Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population	73
High expression of ACE2 and TMPRSS2 and clinical characteristics of COVID-19 in colorectal cancer patients	62
PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma	54
Microbiome dysbiosis in lung cancer: from composition to therapy	50
Quantitative MRI-based radiomics for noninvasively predicting molecular subtypes and survival in glioma patients	50
Multiplex bioimaging of single-cell spatial profiles for precision cancer diagnostics and therapeutics	48
Blood-derived lncRNAs as biomarkers for cancer diagnosis: the Good, the Bad and the Beauty	48
Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy	45
Single-cell analysis of gastric pre-cancerous and cancer lesions reveals cell lineage diversity and intratumoral heterogeneity	45
GD2 CAR T cells against human glioblastoma	42
ACADL plays a tumor-suppressor role by targeting Hippo/YAP signaling in hepatocellular carcinoma	38
The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response	37
Multiplexed drug testing of tumor slices using a microfluidic platform	35
Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance	34
Will polygenic risk scores for cancer ever be clinically useful?	34
Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes	32
Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition	31
Clinical application of a lung cancer organoid (tumoroid) culture system	31
Genetic mutation and biological pathway prediction based on whole slide images in breast carcinoma using deep learning	31
PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer	31

The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib	30
Integrated multiomics analysis of hepatoblastoma unravels its heterogeneity and provides novel druggable targets	28
High TGF-β signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition	28
Dynamic roles of inflammasomes in inflammatory tumor microenvironment	28